Journal article icon

Journal article

Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.

Abstract:

BACKGROUND AND PURPOSE: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modification. MATERIALS AND METHODS: Samples were available from 231 patients with high grade and invasive bladder carcinoma from the BCON phase III trial of radiotherapy (RT) alone or with carbogen and...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Expand authors...
Journal:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Volume:
108
Issue:
1
Pages:
40-47
Publication date:
2013-07-05
DOI:
EISSN:
1879-0887
ISSN:
0167-8140
URN:
uuid:d701436d-8ba0-4988-b0df-1d39d7de0bfe
Source identifiers:
405914
Local pid:
pubs:405914

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP